{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T20:33:36Z","timestamp":1769200416357,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["IIR 16-024"],"award-info":[{"award-number":["IIR 16-024"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["IIR 16-024"],"award-info":[{"award-number":["IIR 16-024"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["IIR 16-024"],"award-info":[{"award-number":["IIR 16-024"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["IIR 16-024"],"award-info":[{"award-number":["IIR 16-024"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018484","name":"Institute for Healthcare Policy and Innovation, University of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018484","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Michigan Integrated Center for Health Analytics and Medical Prediction (MiCHAMP), University of Michigan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Inform Decis Mak"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with hepatitis C virus (HCV) frequently remain at risk for cirrhosis after sustained virologic response (SVR). Existing cirrhosis predictive models for HCV do not account for dynamic antiviral treatment status and are limited by fixed laboratory covariates and short follow up time. Advanced fibrosis assessment modalities, such as transient elastography, remain inaccessible in many settings. Improved cirrhosis predictive models are needed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We developed a laboratory-based model to predict progression of liver disease after SVR. This prediction model used a time-varying covariates Cox model adapted to utilize longitudinal laboratory data and to account for antiretroviral treatment. Individuals were included if they had a history of detectable HCV RNA and at least 2 AST-to-platelet ratio index (APRI) scores available in the national Veterans Health Administration from 2000 to 2015, Observation time extended through January 2019. We excluded individuals with preexisting cirrhosis. Covariates included baseline patient characteristics and 16 time-varying laboratory predictors. SVR, defined as permanently undetectable HCV RNA after antiviral treatment, was modeled as a step function of time. Cirrhosis development was defined as two consecutive APRI scores\u2009&gt;\u20092. We predicted cirrhosis development at 1-, 3-, and 5-years follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In a national sample of HCV patients (n\u2009=\u2009182,772) with a mean follow-up of 6.32\u00a0years, 42% (n\u2009=\u200976,854) achieved SVR before 2016 and 16.2% (n\u2009=\u200929,566) subsequently developed cirrhosis. The model demonstrated good discrimination for predicting cirrhosis across all combinations of laboratory data windows and cirrhosis prediction intervals. AUROCs ranged from 0.781 to 0.815, with moderate sensitivity 0.703\u20130.749 and specificity 0.723\u20130.767.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A novel adaptation of time-varying covariates Cox modeling technique using longitudinal laboratory values and dynamic antiviral treatment status accurately predicts cirrhosis development at 1-, 3-, and 5-years among patients with HCV, with and without SVR. It improves upon earlier cirrhosis predictive models and has many potential population-based applications, especially in settings without transient elastography available.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12911-021-01711-7","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T03:02:21Z","timestamp":1639450941000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adapted time-varying covariates Cox model for predicting future cirrhosis development performs well in a large hepatitis C cohort"],"prefix":"10.1186","volume":"21","author":[{"given":"Lauren A.","family":"Beste","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace L.","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Van","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George N.","family":"Ioannou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Oselio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Tincopa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit G.","family":"Singal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akbar K.","family":"Waljee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"issue":"4","key":"1711_CR1","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.gtc.2015.07.003","volume":"44","author":"S Lingala","year":"2015","unstructured":"Lingala S, Ghany MG. Natural history of hepatitis C. Gastroenterol Clin North Am. 2015;44(4):717\u201334.","journal-title":"Gastroenterol Clin North Am"},{"issue":"9","key":"1711_CR2","doi-asserted-by":"publisher","first-page":"637","DOI":"10.7326\/M16-2575","volume":"166","author":"O Falade-Nwulia","year":"2017","unstructured":"Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis c virus infection: a systematic review. Ann Intern Med. 2017;166(9):637\u201348.","journal-title":"Ann Intern Med"},{"issue":"24","key":"1711_CR3","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1001\/jama.2012.144878","volume":"308","author":"AJ van der Meer","year":"2012","unstructured":"van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584\u201393.","journal-title":"JAMA"},{"issue":"1","key":"1711_CR4","doi-asserted-by":"publisher","first-page":"142.e2","DOI":"10.1053\/j.gastro.2016.09.009","volume":"152","author":"P Nahon","year":"2017","unstructured":"Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology. 2017;152(1):142.e2-56.e2.","journal-title":"Gastroenterology"},{"issue":"10","key":"1711_CR5","doi-asserted-by":"publisher","first-page":"677","DOI":"10.7326\/0003-4819-147-10-200711200-00003","volume":"147","author":"BJ Veldt","year":"2007","unstructured":"Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147(10):677\u201384.","journal-title":"Ann Intern Med"},{"issue":"6","key":"1711_CR6","doi-asserted-by":"publisher","first-page":"509.e1","DOI":"10.1016\/j.cgh.2011.03.004","volume":"9","author":"LI Backus","year":"2011","unstructured":"Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9(6):509.e1-516.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1711_CR7","doi-asserted-by":"crossref","unstructured":"Benhammou JN, Moon AM, Pisegna JR, Su F, Vutien P, Moylan CA, et al. Nonalcoholic fatty liver disease risk factors affect liver-related outcomes after direct-acting antiviral treatment for hepatitis C. Dig Dis Sci. 2020.","DOI":"10.1007\/s10620-020-06457-2"},{"issue":"6","key":"1711_CR8","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/hep.510230607","volume":"23","author":"M Yano","year":"1996","unstructured":"Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996;23(6):1334\u201340.","journal-title":"Hepatology"},{"issue":"23","key":"1711_CR9","first-page":"2296","volume":"377","author":"EB Tapper","year":"2017","unstructured":"Tapper EB, Lok ASF. Use of liver imaging and biopsy in clinical practice. N Engl J Med. 2017;377(23):2296\u20137.","journal-title":"N Engl J Med"},{"issue":"5","key":"1711_CR10","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/jvh.12846","volume":"25","author":"A Erman","year":"2018","unstructured":"Erman A, Sathya A, Nam A, Bielecki JM, Feld JJ, Thein HH, et al. Estimating chronic hepatitis C prognosis using transient elastography-based liver stiffness: a systematic review and meta-analysis. J Viral Hepat. 2018;25(5):502\u201313.","journal-title":"J Viral Hepat"},{"issue":"2","key":"1711_CR11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.dld.2018.11.016","volume":"51","author":"HD Trivedi","year":"2019","unstructured":"Trivedi HD, Patwardhan VR, Malik R. Chronic hepatitis C infection\u2014Noninvasive assessment of liver fibrosis in the era of direct acting antivirals. Dig Liver Dis. 2019;51(2):183\u20139.","journal-title":"Dig Liver Dis"},{"issue":"10","key":"1711_CR12","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1136\/gut.2010.207423","volume":"59","author":"RJ Fontana","year":"2010","unstructured":"Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, et al. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut. 2010;59(10):1401\u20139.","journal-title":"Gut"},{"issue":"11","key":"1711_CR13","doi-asserted-by":"publisher","first-page":"e0187344","DOI":"10.1371\/journal.pone.0187344","volume":"12","author":"MA Konerman","year":"2017","unstructured":"Konerman MA, Lu D, Zhang Y, Thomson M, Zhu J, Verma A, et al. Assessing risk of fibrosis progression and liver-related clinical outcomes among patients with both early stage and advanced chronic hepatitis C. PLoS ONE. 2017;12(11):e0187344.","journal-title":"PLoS ONE"},{"key":"1711_CR14","doi-asserted-by":"crossref","unstructured":"Konerman MA, Zhang Y, Zhu J, Higgins PD, Lok AS, Waljee AK. Improvement of predictive models of risk of disease progression in chronic hepatitis C by incorporating longitudinal data. Hepatology. 2015.","DOI":"10.1002\/hep.27750"},{"issue":"1","key":"1711_CR15","doi-asserted-by":"publisher","first-page":"e0208141","DOI":"10.1371\/journal.pone.0208141","volume":"14","author":"MA Konerman","year":"2019","unstructured":"Konerman MA, Beste LA, Van T, Liu B, Zhang X, Zhu J, et al. Machine learning models to predict disease progression among veterans with hepatitis C virus. PLoS ONE. 2019;14(1):e0208141.","journal-title":"PLoS ONE"},{"issue":"2","key":"1711_CR16","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","volume":"38","author":"CT Wai","year":"2003","unstructured":"Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518\u201326.","journal-title":"Hepatology"},{"issue":"9","key":"1711_CR17","doi-asserted-by":"publisher","first-page":"516","DOI":"10.6061\/clinics\/2017(09)01","volume":"72","author":"TG Ragazzo","year":"2017","unstructured":"Ragazzo TG, Paranagua-Vezozzo D, Lima FR, de Campos Mazo DF, Pessoa MG, Oliveira CP, et al. Accuracy of transient elastography-FibroScan(R), acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C. Clinics (Sao Paulo). 2017;72(9):516\u201325.","journal-title":"Clinics (Sao Paulo)"},{"issue":"5","key":"1711_CR18","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/ajg.2016.453","volume":"112","author":"S McPherson","year":"2017","unstructured":"McPherson S, Hardy T, Dufour JF, Petta S, Romero-Gomez M, Allison M, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112(5):740\u201351.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"1711_CR19","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s10620-019-05886-y","volume":"65","author":"R Huang","year":"2020","unstructured":"Huang R, Rao H, Yang M, Gao Y, Wang J, Jin Q, et al. Noninvasive measurements predict liver fibrosis well in hepatitis c virus patients after direct-acting antiviral therapy. Dig Dis Sci. 2020;65(5):1491\u2013500.","journal-title":"Dig Dis Sci"}],"container-title":["BMC Medical Informatics and Decision Making"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-021-01711-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12911-021-01711-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-021-01711-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T07:03:26Z","timestamp":1646982206000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedinformdecismak.biomedcentral.com\/articles\/10.1186\/s12911-021-01711-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1711"],"URL":"https:\/\/doi.org\/10.1186\/s12911-021-01711-7","relation":{},"ISSN":["1472-6947"],"issn-type":[{"value":"1472-6947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"24 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval to conduct the study was gained from the Institutional Review Board at the VA Ann Arbor Healthcare System and informed consent from patients was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Lauren A. Beste, MD, MSc: None. Xuefei Zhang, MS: None. Grace Su, MD: Is an equity owner of Applied Morphomics and Prenovo. Dr. Su has a patent with the University of Michigan regarding image analysis of liver disease. Dr. Su has received funding from the NIH, VA and DoD. No conflicts with this manuscript. Tony Van, MS: None. George N. Ioannou, MD, MS: None. Monica Tincopa, MD, MSc: None. Boang Liu, PhD: None. Amit Singal, MD: Has received research funding from Gilead and Abbvie. Ji Zhu, PhD: None. Akbar K. Waljee, MD, MSc: None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"347"}}